With the exception of the tumor with GNAQ and KRAS co-mutation, all MAPK-activating hotspot mutations appeared to be mutually exclusive of each other and amplifications of MAPK pathway genes (Figure 3). The gene discussed is KRAS; the disease is neoplasm.